Release Date: June 6, 2025
Expiration Date: June 6, 2026
Time to Complete Activity: 1.0 hour

Faculty 

Joseph M. Coney, MD, FASRS, FACS—Chairperson
Retina Associates of Cleveland Inc
Clinical Senior Instructor
Case Western Reserve University
Cleveland, OH

Steven Ferrucci, OD, FAAO
Chief, Optometry Section
Sepulveda VA Medical Center
Professor
Marshall B. Ketchum University/Southern California College of Optometry
Fullerton, CA

Veeral Sheth, MD, MBA
Partner and Director, Clinical Research 
University Retina and Macula Associates
Clinical Assistant Professor
University of Illinois at Chicago
Chicago, IL
 

Target Audience 

This activity has been designed to meet the educational needs of retina specialists, comprehensive ophthalmologists, and optometrists. It may also benefit other clinicians involved in the care of patients with diabetic eye disease.
 

Educational Providers 

This activity is provided by Paradigm Medical Communications, LLC. 

In collaboration with New England College of Optometry (NECO). 
 

Supporter Acknowledgment 

This activity is supported by an educational grant from Genentech, a member of the Roche Group.
 

Program Overview 

Eye care specialists examine the causes and potential solutions to barriers that create inequities in diabetic eye care, from screening to treatment. Learners will engage with a robust discussion of strategies to optimize the care of racial/ethnic minorities with, or at risk for, diabetic eye disease, including recent data addressing the unmet needs of these groups in clinical trials.
 

Learning Objectives

Upon completion of this activity, participants should be able to:

• Recognize differences in the impact of diabetic eye disease on various racial/ethnic minorities 
• Implement strategies that may improve diabetic eye care in racial/ethnic minority groups 
• Describe evidence demonstrating the effects of anti-vascular endothelial growth factor (VEGF) treatment on racial/ethnic minorities versus White patients 
• Discuss novel therapies that are being studied in trials that have high representation of racial/ethnic minorities

Physician Accreditation Statement

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 

Physician Credit Designation Statement

Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Optometrist Continuing Education

This activity, COPE Activity Number 130878, is accredited by COPE for continuing education for optometrists.

COPE Course ID: 98066-PB
COPE Activity ID: 130878

Please consult your state’s Board of Optometry to determine if the CE credit may apply toward your CE requirement for license renewal.  
 

PA Continuing Education 

PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
 

Nurse Practitioner Continuing Education 

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
 

Hardware/Software Requirements

This accredited CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader

Technical Support: If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.
 

Instructions for Participation

To receive a certificate of participation, participants must:

• Follow instructions to register or log in with your professional information and complete the pretest
• View the online activity in its entirety
• Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com.

There are no fees for participating in this activity.

Disclosure of Relevant Financial Relationships

In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.

All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated.

Joseph M. Coney, MD, FASRS, FACS—Chairperson
Advisor: AbbVie Inc.; Alimera Sciences (expired 9/24); Apellis Pharmaceuticals, Inc; Genentech, Inc.; Regeneron Pharmaceuticals Inc (expired 6/23)
Consultant: Bausch & Lomb; Coherus BioSciences
Speakers’ Bureau: AbbVie Inc.; Alimera Sciences (expired 9/24); Apellis Pharmaceuticals, Inc; Astellas Pharma US, Inc; Genentech, Inc.; Novartis AG (expired 6/23); Regeneron Pharmaceuticals Inc (expired 6/23)
Research Funding: 4D Molecular Therapeutics; AbbVie, Inc.; Alimera Sciences (expired 2/25); Apellis Pharmaceuticals, Inc; Aviceda Therapeutics; Eyebiotech Limited; F. Hoffmann-La Roche AG; Genentech, Inc.; MacTel; Neurotech Pharmaceuticals, Inc; Novartis AG (expired 6/23); Regeneron Pharmaceuticals Inc (expired 6/23); REGENXBIO Inc

Steven Ferrucci, OD, FAAO
Consultant: ScienceBased Health; Visible Genomics
Speakers’ Bureau: Apellis Pharmaceuticals, Inc; Astellas Pharma US, Inc; iCare Health Solutions; LKC Technologies

Veeral Sheth, MD, MBA
Consultant: Alkeus Pharmaceuticals; Apellis Pharmaceuticals, Inc; Boehringer Ingelheim International GmbH; EyePoint Pharmaceuticals, Inc; Genentech, Inc.; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; Kriya Therapeutics; Novartis AG; Ocular Therapeutix, Inc; Oculis; Ocuphire Pharma, Inc; Ollin Biosciences Inc.; Opthea; Regeneron Pharmaceuticals Inc; RevOpsis Therapeutics LLC; UNITY Biotechnology; Vial
Speakers’ Bureau: Genentech, Inc.
Research Funding: 4D Molecular Therapeutics; AbbVie Inc.; Adverum Biotechnologies, Inc; Alimera Sciences; Ashvattha Therapeutics; Astellas Pharma US, Inc; Aviceda Therapeutics; Chengdu Kanghong Pharmaceutical Group Co, LTD; Eluminex Biosciences; Eyebiotech Limited; EyePoint Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Genentech, Inc.; Gyroscope Therapeutics Limited; i-Lumen Scientific; Ionis Pharmaceuticals; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; NGM Biopharmaceuticals; Novartis AG; Ocular Therapeutix, Inc; Oculis; Ocugen, Inc; OcuTerra Therapeutics; Olix Pharmaceuticals, Inc; Opthea; Outlook Therapeutics, Inc; Oxular Limited; Oxurion NV; Perfuse Therapeutics; RecensMedical, Inc; Regeneron Pharmaceuticals Inc; REGENXBIO Inc; Rezolute, Inc.; SalutarisMD; Sam Chun Dang Pharm Co.,Ltd.; Santen Pharmaceutical Co., Ltd.; Smilebiotek Zhuhai Limited; UNITY Biotechnology; Vanotech Ltd.

Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.

NECO Staff Reviewer
Advisor: Sight Sciences (expired 6/24)

Peer Reviewer
Stock: CytomX Therapeutics Inc (expired 1/25); F. Hoffmann-La Roche Ltd (expired 3/24); Medtronic (expired 3/24); Pfizer Inc. (expired 3/24)

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

Disclaimer

This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
 

Contact Us

If you have any questions or comments, please email us at contactus@paradigmmc.com.

© 2025 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.